Key facts
- This page summarizes Keli Walbert's Form 4 filing for Hemab Therapeutics Holdings, Inc. (COAG).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 25 Sep 2026, 16:45.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
This option was granted on September 24, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from September 24, 2026 through September 24, 2029, subject to continuous service.